WCN26-3834 Combination Therapy with Tolvaptan and Everolimus in Two Adult Sisters with PKD1/TSC2 Contiguous Gene Syndrome

Read full text Summarise with VIRAT
Authors: Satoru Muto, Shigeo Horie, Haruna Kawano
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

PKD1/TSC2 contiguous gene syndrome (CGS) is a rare disorder caused by a large chromosomal deletion involving both the PKD1 and TSC2 genes on chromosome 16p13.3, resulting in clinical manifestations of both autosomal dominant polycystic kidney disease (ADPKD) and tuberous sclerosis complex (TSC). While tolvaptan, a vasopressin V2 receptor antagonist, has been proven to slow kidney volume growth and renal function decline in ADPKD, and everolimus, an mTOR inhibitor, is effective in reducing renal angiomyolipoma (AML) size in TSC, no previous reports have described their combined use in PKD1/TSC2 CGS.

Fields of Study & Subjects

Tuberous Sclerosis Complex Research Genetic and Kidney Cyst Diseases Renal cell carcinoma treatment

Publication details

Journal / source
Kidney International Reports
Volume
11
Issue
4
Pages
105733–105733
Publication date
25 March 2026
Language
EN